Zobrazeno 1 - 10
of 18
pro vyhledávání: '"P G Kotze"'
Autor:
Thaisa Kowalski Furlan, Marcello Imbrizi, Daniela Magro, Paula C. Senger de Castro, Rodrigo Bremer Nones, Eron Fabio Miranda, Paulo G. Kotze
Publikováno v:
Journal of Coloproctology, Vol 44, Iss 03, Pp e187-e195 (2024)
Introduction and Objectives Certolizumab Pegol (CZP) is an anti-TNF agent approved in Brazil for Crohn's disease (CD). There is a lack of data in Brazil and Latin America detailing real-world experiences with CZP. The primary objective was clinical r
Externí odkaz:
https://doaj.org/article/824343b1774646e0be3b27e0774e6b7c
Autor:
David T. Rubin, Leonardo Salese, Mitchell Cohen, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objective: To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk fac
Externí odkaz:
https://doaj.org/article/4f14d6481d204724942026dae5b142a5
Autor:
Abel B. Quaresma, Aderson O.M.C. Damiao, Claudio S.R. Coy, Daniela O. Magro, Adriano A.F. Hino, Douglas A. Valverde, Remo Panaccione, Stephanie B. Coward, Siew C. Ng, Gilaad G. Kaplan, Paulo G. Kotze
Publikováno v:
The Lancet Regional Health. Americas, Vol 13, Iss , Pp 100298- (2022)
Summary: Background: Population-based data on epidemiology of Inflammatory Bowel Diseases (IBD) in Brazil are scarce. This study aims to define temporal trends of incidence and prevalence rates of Crohn's disease (CD) and ulcerative colitis (UC) in B
Externí odkaz:
https://doaj.org/article/a7d5e271f4e9493dbb013360e71e7f28
Autor:
David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo G. Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with
Externí odkaz:
https://doaj.org/article/e097ca53b86849d19e2e7355909c6a94
Autor:
Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho
Publikováno v:
Intestinal Research, Vol 16, Iss 4, Pp 522-528 (2018)
Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare
Externí odkaz:
https://doaj.org/article/c5c9bafdb482423aaf5c56a8aa60cdab
Autor:
Marley R. Feitosa, Rogério S. Parra, Vanessa F. Machado, Gustavo N. Vilar, Jussara C. Aquino, José J. R. Rocha, Paulo G. Kotze, Omar Féres
Publikováno v:
Gastroenterology Research and Practice, Vol 2021 (2021)
Background and Aims. Patients may experience complications of Crohn’s disease (CD) even when treated with optimal medical therapy strategies. Previous data have shown the efficacy of hyperbaric oxygen therapy (HBOT) in the management of complicated
Externí odkaz:
https://doaj.org/article/cc5e8fd06ebb4071803bb4ca1c76e418
Autor:
A C V Silva, T J Tumelero, D O Magro, D R Yamamoto, L B M Ribeiro, G S da Silva, S K Truppel, M C Vieira, P G Kotze MD- PhD
Publikováno v:
Journal of Crohn's and Colitis. 17:i957-i958
Background There is lack of epidemiological data in regard to the accurate situation of Inflammatory Bowel Disease (IBD): Crohn’s disease (CD) and ulcerative colitis (UC) in Brazil. It is known that both diseases' progression is variable and the ch
Autor:
A Z Dotti, E G Vilela, J M F Chebli, L A Chebli, D O Magro, F Steinwurz, M Argollo, N S Carvalho, J M L Parente, R S Parra, R L Perin, C Flores, E M Morsoletto, S D C Ferreira, J C Ludvig, R L Kaiser Jr, N S F Queiroz, M A G Faria, G M Nicollelli, A R Andrade, P G Kotze
Publikováno v:
Journal of Crohn's and Colitis. 17:i714-i715
Background Vedolizumab, a human monoclonal antibody that blocks integrin α4-β7, was approved for the management of Inflammatory Bowel Diseases. In real-world experience the number of patients using vedolizumab as first-line biological therapy was l
Autor:
S Vermeire, L Peyrin-Biroulet, J Panés, M Regueiro, P G Kotze, A Charabaty, M Goetsch, K Shan, J Wu, A McDonnell, J Woolcott, S Danese
Publikováno v:
Journal of Crohn's and Colitis. 17:i619-i620
Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). The safety and efficacy of
Publikováno v:
Journal of Crohn's and Colitis. 17:i587-i587
Background Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the intestine, have a rising incidence and prevalence globally. The potential impact of socioeconomic inequality